STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #976 by analyst upside · 2026-06-27
CSTL
Castle Biosciences, Inc.
Healthcare · Market Cap $737M · P/E 0x
ANALYST PRICE TARGET
+79.2%
implied upside to consensus target
Current Price $24.3
Consensus Target $43.56
Bull Target $52.0
Bear Target $35.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
9
Hold
0
Sell
0
52-Week Low $14.59
52-Week High $44.28
YTD Return -36.9%
FUNDAMENTALS
Market Cap $737M
P/E Ratio (TTM) N/A
Forward P/E -26.0x
EPS (TTM) $-0.42
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $340M
Profit Margin -3.8%
52-WEEK RANGE
52-Week Low $14.59
52-Week High $44.28
Current Price $24.3
Bear Target $35.0
Bull Target $52.0
● Now $24.3 ● Target $43.56
TRADING DATA
Avg Volume 388K
YTD Return -36.9%
Analyst Count 9
Consensus Buy
Upside to Target +79.2%
Last Updated 2026-06-27

ANALYST SUMMARY

Castle Biosciences, Inc. (CSTL) is currently trading at $24.3 with a Wall Street consensus price target of $43.56, implying potential upside of 79.2% over the next 12 months. 9 analysts currently cover CSTL, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $52.0, while the most cautious has a target of $35.0.

CSTL operates in the Healthcare sector with a market capitalisation of $737M. The stock is down 36.9% year-to-date and is currently trading near the lower end of its 52-week range of $14.59 – $44.28.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CSTL, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG — Reiterated
Buy → Buy 2026-05-13 38% win rate (8 calls)
Baird — Reiterated
Outperform → Outperform 2026-05-07 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-04-20 Building track record
Baird — Reiterated
Outperform → Outperform 2026-02-27 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-01-26 62% win rate (8 calls)
Lake Street — Reiterated
Buy → Buy 2026-01-12 27% win rate (11 calls)
Guggenheim — Reiterated
Buy → Buy 2026-01-05 62% win rate (8 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2025-12-22 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
61
out of 100
Coverage depth
18/30
Consensus clarity
16/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →